Critical Reviews in Oncology / Hematology
Volume 79, Issue 3 , Pages 293-301 , September 2011

Management strategy of early-stage breast cancer patients with a positive sentinel lymph node: With or without axillary lymph node dissection

  • Jia-Jian Chen

      Affiliations

    • Department of Breast Surgery, Cancer Hospital/Cancer Institute, Fudan University, China
    • Department of Oncology, Shanghai Medical College, Fudan University, China
    • ,
  • Jiong Wu

      Affiliations

    • Department of Breast Surgery, Cancer Hospital/Cancer Institute, Fudan University, China
    • Department of Oncology, Shanghai Medical College, Fudan University, China
    • Corresponding Author InformationCorresponding author at: Department of Breast Surgery, Cancer Hospital/Cancer Institute, Breast Cancer Institute, Fudan University, 399 Ling-Ling Road, Shanghai 200032, China. Fax: +86 21 64434556.

,Accepted 25 June 2010.

References 

  1. Quiet CA, Ferguson DJ, Weichselbaum RR, et al. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol. 1995;13(May (5)):1144–1151
  2. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(September (3)):391–398[discussion 398–401]
  3. Cady B, Stone MD, Schuler JG, et al. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg. 1996;131(March (3)):301–308
  4. Tabár L, Fagerberg G, Day NE, et al. Breast cancer treatment and natural history: new insights from results of screening. Lancet. 1992;339(February (8790)):412–414
  5. Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?. Cancer. 1994;73(February (3)):664–667
  6. Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a “sentinel node” in cancer of the parotid. Cancer. 1960;13(January–February):77–78
  7. McCready D, Holloway C, Shelley W, et al. Surgical management of early stage invasive breast cancer: a practice guideline. Can J Surg. 2005;48(June (3)):185–194
  8. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(October (30)):7703–7720
  9. Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18(July (13)):2553–2559
  10. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(August (6)):546–553
  11. Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7(December (12)):983–990
  12. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(May (9)):599–609
  13. Chen JJ, Huang XY, Liu ZB, et al. Sentinel node biopsy and quality of life measures in a Chinese population. Eur J Surg Oncol. 2009;35(September (9)):921–927
  14. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349(June (9069)):1864–1867
  15. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15(June (6)):2345–2350
  16. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med. 1998;339(October (14)):941–946
  17. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312(March (11)):674–681
  18. White RE, Vezeridis MP, Konstadoulakis M, et al. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg. 1996;183(December (6)):575–582
  19. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol. 1999;6(January–February (1)):109–116
  20. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7(February (2)):122–192
  21. Straver M, Meijnen P, van Tienhoven G, et al. Current status of the EORTC 10981-22023 AMAROS trial—after mapping of the axilla radiotherapy or surgery. Eur J Cancer. 2008;6(April (Suppl. 7)):147
  22. Galimberti V. International Breast Cancer Study Group Trial of sentinel node biopsy. J Clin Oncol. 2006;24(January (1)):210–211
  23. White RL, Wilke LG. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg. 2004;70(May (5)):420–424
  24. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(December (10)):1140–1151
  25. Ozmen V, Karanlik H, Cabioglu N, et al. Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat. 2006;95(January (1)):1–6
  26. Barranger E, Coutant C, Flahault A, et al. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91(May (2)):113–119
  27. Cody HS, Van Zee KJ. Predicting nonsentinel node metastases in sentinel node-positive breast cancer: what have we learned, can we do better, and do we need to?. Ann Surg Oncol. 2008;15(November (11)):2998–3002
  28. Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 1894;20(November (5)):497–555
  29. Consensus statement: treatment of early-stage breast cancer . National Institutes of Health Consensus Development Panel. J Natl Cancer Inst Monogr. 1992;(11):1–5
  30. Petrek JA, Blackwood MM. Axillary dissection: current practice and technique. Curr Probl Surg. 1995;32(April (4)):257–323
  31. Schaapveld M, de Vries EG, van der Graaf WT, Otter R, de Vries J, Willemse PH. The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association?. Ann Surg Oncol. 2006;13(April (4)):465–474
  32. Axelsson CK, Düring M, Christiansen PM, et al. Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer. Br J Surg. 2009;96(January (1)):40–46
  33. Axelsson CK, Mouridsen HT, Düring M, Møller S. Axillary staging during surgery for breast cancer. Br J Surg. 2007;94(March (3)):304–309
  34. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet. 1981;152(June (6)):765–772
  35. Fisher B, Fisher ER. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet. 1966;122(April (4)):791–798
  36. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320(March (13)):822–828
  37. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(August (8)):567–575
  38. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337(October (14)):956–962
  39. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337(October (14)):949–955
  40. Quan ML, McCready D. The evolution of lymph node assessment in breast cancer. J Surg Oncol. 2009;99(March (4)):194–198
  41. Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol. 2003;10(December (10)):1152–1159
  42. Polednak AP. Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Ann Surg. 2003;237(February (2)):163–167
  43. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(December (9503)):2087–2106
  44. Camp RL, Rimm EB, Rimm DL. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer. 2000;88(January (1)):108–113
  45. Vinh-Hung V, Burzykowski T, Cserni G, Voordeckers M, Van De Steene J, Storme G. Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol. 2003;22(March (3)):697–704
  46. Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res. 1999;84(June (2)):138–142
  47. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106(January (1)):4–16
  48. Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233(January (1)):51–59
  49. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18(July (13)):2560–2566
  50. Schrenk P, Rehberger W, Shamiyeh A, Wayand W. Sentinel node biopsy for breast cancer: does the number of sentinel nodes removed have an impact on the accuracy of finding a positive node?. J Surg Oncol. 2002;80(July (3)):130–136
  51. Zakaria S, Degnim AC, Kleer CG, et al. Sentinel lymph node biopsy for breast cancer: how many nodes are enough?. J Surg Oncol. 2007;96(December (7)):554–559
  52. Dabbs DJ, Johnson R. The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J. 2004;10(May–June (3)):186–189
  53. Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer. 2001;92(September (6)):1378–1384
  54. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer. 1997;80(October (7)):1188–1197
  55. Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999;354(September (9182)):896–900
  56. Pargaonkar AS, Beissner RS, Snyder S, Speights VO. Evaluation of immunohistochemistry and multiple-level sectioning in sentinel lymph nodes from patients with breast cancer. Arch Pathol Lab Med. 2003;127(June (6)):701–705
  57. Abdul-Rasool S, Kidson SH, Panieri E, et al. An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. J Clin Pathol. 2006;59(3):289–297
  58. Langer I, Guller U, Hsu-Schmitz SF, et al. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol. 2009;35(August (8)):805–813
  59. In:  Edge SB,  Byrd DR,  Compton CC,  Fritz AG,  Greene FL,  Trotti A editor. AJCC cancer staging manual. 7th ed.. New York, NY: Springer; 2010;
  60. Chagpar AB, McMasters KM. Treatment of sentinel node-positive breast cancer. Expert Rev Anticancer Ther. 2006;6(August (8)):1233–1239[Review]
  61. Yu JC, Hsu GC, Hsieh CB, Sheu LF, Chao TY. Prediction of metastasis to non-sentinel nodes by sentinel node status and primary tumor characteristics in primary breast cancer in Taiwan. World J Surg. 2005;29(July (7)):813–818[discussion 818–9]
  62. van Iterson V, Leidenius M, Krogerus L, von Smitten K. Predictive factors for the status of non-sentinel nodes in breast cancer patients with tumor positive sentinel nodes. Breast Cancer Res Treat. 2003;82(November (1)):39–45
  63. Grabau D. Breast cancer patients with micrometastases only: is a basis provided for tailored treatment?. Surg Oncol. 2008;17(September (3)):211–217
  64. Cserni G, Gregori D, Merletti F, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91(October (10)):1245–1252
  65. Hwang RF, Krishnamurthy S, Hunt KK, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;10(April (3)):248–254
  66. Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95(March (3)):302–309
  67. Kohrt HE, Olshen RA, Bermas HR, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8(March):66
  68. Smidt ML, Kuster DM, van der Wilt GJ, Thunnissen FB, Van Zee KJ, Strobbe LJ. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands?. Ann Surg Oncol. 2005;12(December (12)):1066–1072[Epub 2005 October 26]
  69. Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003;98(December (11)):2307–2315
  70. Houvenaeghel G, Nos C, Giard S, et al. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol. 2009;35(July (7)):690–695[Epub 2008 November 28]
  71. Cserni G, Amendoeira I, Apostolikas N, et al. Review of current data to be considered for the formulation of guidelines. Eur J Cancer. 2003;39(August (12)):1654–1667
  72. Poirier E, Sideris L, Dubé P, Drolet P, Meterissian SH. Analysis of clinical applicability of the breast cancer nomogram for positive sentinel lymph node: the Canadian experience. Ann Surg Oncol. 2008;15(September (9)):2562–2567[Epub 2008 July 10]
  73. Houvenaeghel G, Nos C, Giard S, et al. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol. 2009;35(July (7)):690–695
  74. Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245(March (3)):462–468
  75. Zgajnar J, Perhavec A, Hocevar M, et al. Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol. 2007;96(December (7)):547–553
  76. Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89(August (3)):574–581
  77. Chu KU, Turner RR, Hansen NM, Brennan MB, Giuliano AE. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol. 1999;6(December (8)):756–761
  78. Alran S, De Rycke Y, Fourchotte V, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol. 2007;14(August (8)):2195–2201
  79. de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361(August (7)):653–663
  80. Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg. 2000;232(July (1)):1–7
  81. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(June (18)):2946–2953[Epub 2009 April 13]
  82. Rutgers EJ. Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. J Clin Oncol. 2008;26(February (5)):698–702
  83. Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005;12(August (8)):654–659
  84. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol. 2001;20(April–May (3)):230–237

PII: S1040-8428(10)00151-4

doi: 10.1016/j.critrevonc.2010.06.008

Critical Reviews in Oncology / Hematology
Volume 79, Issue 3 , Pages 293-301 , September 2011

Article Tools